Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 17 | 2014 | 2431 | 1.300 |
Why?
|
| Cystectomy | 5 | 2014 | 635 | 0.560 |
Why?
|
| CA-125 Antigen | 1 | 2017 | 229 | 0.540 |
Why?
|
| BCG Vaccine | 4 | 2014 | 428 | 0.530 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 499 | 0.440 |
Why?
|
| Adjuvants, Immunologic | 3 | 2014 | 695 | 0.430 |
Why?
|
| Prostatectomy | 5 | 2011 | 1003 | 0.380 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 60 | 0.360 |
Why?
|
| Cystoscopy | 1 | 2010 | 92 | 0.350 |
Why?
|
| Fluorescence | 1 | 2010 | 198 | 0.350 |
Why?
|
| Muscle Neoplasms | 1 | 2011 | 108 | 0.350 |
Why?
|
| Prostatic Neoplasms | 8 | 2015 | 5860 | 0.330 |
Why?
|
| Carcinoma | 2 | 2011 | 2609 | 0.330 |
Why?
|
| Prostate-Specific Antigen | 4 | 2007 | 1029 | 0.300 |
Why?
|
| Urology | 1 | 2009 | 140 | 0.290 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2007 | 56 | 0.290 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2929 | 0.280 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 4795 | 0.260 |
Why?
|
| Databases, Factual | 2 | 2009 | 2251 | 0.240 |
Why?
|
| MicroRNAs | 2 | 2017 | 2886 | 0.240 |
Why?
|
| Urothelium | 4 | 2012 | 264 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 9 | 2014 | 4048 | 0.220 |
Why?
|
| Follistatin | 1 | 2023 | 55 | 0.220 |
Why?
|
| Precision Medicine | 1 | 2011 | 1208 | 0.210 |
Why?
|
| Catheter Ablation | 1 | 2007 | 575 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 3845 | 0.170 |
Why?
|
| Treatment Outcome | 11 | 2017 | 33733 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 2388 | 0.150 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 1822 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 4963 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 3108 | 0.130 |
Why?
|
| Watchful Waiting | 2 | 2015 | 293 | 0.130 |
Why?
|
| Humans | 33 | 2023 | 270744 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2017 | 9473 | 0.120 |
Why?
|
| DNA Contamination | 1 | 2013 | 3 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 2651 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 210 | 0.110 |
Why?
|
| Preoperative Care | 2 | 2017 | 1565 | 0.110 |
Why?
|
| Registries | 3 | 2014 | 2209 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2012 | 10706 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 4328 | 0.100 |
Why?
|
| Aged | 12 | 2017 | 73375 | 0.100 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 220 | 0.100 |
Why?
|
| Urinary Bladder | 1 | 2014 | 593 | 0.100 |
Why?
|
| Middle Aged | 14 | 2017 | 90334 | 0.100 |
Why?
|
| Prognosis | 7 | 2017 | 22480 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 5102 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 432 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 566 | 0.090 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2010 | 33 | 0.090 |
Why?
|
| Muscles | 1 | 2012 | 456 | 0.090 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 123 | 0.090 |
Why?
|
| Time Factors | 5 | 2014 | 13021 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2012 | 202 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 5231 | 0.080 |
Why?
|
| HeLa Cells | 1 | 2013 | 1685 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2012 | 427 | 0.080 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 288 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 489 | 0.080 |
Why?
|
| Cell Transdifferentiation | 1 | 2009 | 114 | 0.080 |
Why?
|
| Biopsy | 2 | 2007 | 3483 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2010 | 447 | 0.080 |
Why?
|
| Patient Selection | 2 | 2013 | 2026 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 147 | 0.080 |
Why?
|
| Male | 16 | 2015 | 128374 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2009 | 223 | 0.070 |
Why?
|
| Mesoderm | 1 | 2009 | 392 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 4963 | 0.070 |
Why?
|
| Epithelium | 1 | 2009 | 782 | 0.070 |
Why?
|
| Robotics | 1 | 2011 | 365 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2010 | 3045 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 9039 | 0.070 |
Why?
|
| Lymph Node Excision | 2 | 2012 | 2062 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 1301 | 0.060 |
Why?
|
| Models, Biological | 2 | 2011 | 3194 | 0.060 |
Why?
|
| Female | 10 | 2023 | 148945 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2023 | 5403 | 0.060 |
Why?
|
| Neoplasm Staging | 5 | 2014 | 14012 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1457 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5310 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 14616 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2453 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1902 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 251 | 0.060 |
Why?
|
| Apoptosis | 3 | 2012 | 7754 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2009 | 999 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2006 | 728 | 0.050 |
Why?
|
| Forecasting | 1 | 2005 | 702 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2005 | 368 | 0.050 |
Why?
|
| Hypogonadism | 1 | 2005 | 278 | 0.050 |
Why?
|
| Immunotherapy | 2 | 2006 | 3557 | 0.050 |
Why?
|
| Length of Stay | 1 | 2007 | 2004 | 0.040 |
Why?
|
| Testosterone | 1 | 2005 | 638 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 16669 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 14838 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 2311 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2012 | 31006 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2012 | 5440 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2006 | 1465 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 6255 | 0.030 |
Why?
|
| Mass Screening | 1 | 2005 | 1548 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2011 | 5675 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 5171 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7915 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 4001 | 0.030 |
Why?
|
| Disease Progression | 3 | 2012 | 6855 | 0.030 |
Why?
|
| North America | 1 | 2014 | 337 | 0.030 |
Why?
|
| Vinblastine | 1 | 2014 | 462 | 0.030 |
Why?
|
| Caspase Inhibitors | 1 | 2012 | 95 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 657 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2012 | 10260 | 0.030 |
Why?
|
| Glycosylation | 1 | 2012 | 230 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 135 | 0.030 |
Why?
|
| Adult | 5 | 2012 | 81975 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2012 | 169 | 0.030 |
Why?
|
| United States | 1 | 2009 | 15853 | 0.020 |
Why?
|
| Animals | 4 | 2012 | 62045 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 606 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 266 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2014 | 39827 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 1025 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 558 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2010 | 206 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 691 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 1054 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 350 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2023 | 7237 | 0.020 |
Why?
|
| SEER Program | 1 | 2014 | 1047 | 0.020 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2009 | 25 | 0.020 |
Why?
|
| Caspases | 1 | 2012 | 679 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 249 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2012 | 271 | 0.020 |
Why?
|
| Mice | 2 | 2012 | 35594 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 474 | 0.020 |
Why?
|
| Video Recording | 1 | 2011 | 281 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 5149 | 0.020 |
Why?
|
| Pelvis | 1 | 2011 | 381 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 589 | 0.020 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 261 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 895 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 1389 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 562 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2015 | 13414 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 757 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 2091 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 3145 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 2496 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 657 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 1387 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 17896 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 1002 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 4329 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 5759 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 3448 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 9041 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 767 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 3588 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2196 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3919 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2009 | 1503 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 6768 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 1428 | 0.010 |
Why?
|
| Body Composition | 1 | 2005 | 607 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12526 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2009 | 2376 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 6447 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 7383 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 3346 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 2238 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 6192 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 12102 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 10385 | 0.010 |
Why?
|